The Emerging Role of TYRO3 as a Therapeutic Target in Cancer

Por Smart, Sherri K., Vasileiadi, Eleana, Wang, Xiaodong, DeRyckere, Deborah, Graham, Douglas K.
Publicado no Cancers (Basel) (2018)

Data-driven construction of anti-tumor agents with controlled polypharmacology

Por Da, Chenxiao, Zhang, Dehui, Stashko, Michael, Vasileiadi, Eleana, Parker, Rebecca, Minson, Katherine A., Huey, Madeline G., Huelse, Justus M., Hunter, Debra, Gilbert, Thomas S. K., Norris-Drouin, Jacqueline, Miley, Michael, Herring, Laura E., Graves, Lee M., DeRyckere, Deborah, Earp, H. Shelton, Graham, Douglas, Frye, Stephen V., Wang, Xiaodong, Kireev, Dmitri
Publicado no J Am Chem Soc (2019)

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents

Por McDaniel, Nellie K., Cummings, Christopher T., Iida, Mari, Hülse, Justus, Pearson, Hannah E., Vasileiadi, Eleana, Parker, Rebecca E., Orbuch, Rachel A., Ondracek, Olivia J., Welke, Noah B., Kang, Grace Hye-Hyun, Davies, Kurtis D., Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Harari, Paul M., Kimple, Randall J., DeRyckere, Deborah, Graham, Douglas K., Wheeler, Deric L.
Publicado no Mol Cancer Ther (2018)